Jeffrey M. Dayno, M.D., is the President and Chief Executive Officer of Harmony Biosciences Holdings Inc., a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for rare neurological diseases. Appointed to his current role in 2020, Dr. Dayno has spearheaded the company's growth, overseeing the successful U.S. launch and commercialization of WAKIX® (pitolisant HCl) tablets, the first-and-only treatment for both cataplexy and excessive daytime sleepiness in adult patients with narcolepsy. Under his leadership, Harmony has achieved significant revenue milestones, expanded its commercial infrastructure, and advanced a robust pipeline targeting underserved patient populations in sleep/wake disorders and other rare conditions. A board-certified neurologist with over 25 years of experience in the pharmaceutical industry, Dr. Dayno previously served as Senior Vice President and Head of Medical Affairs at Sunovion Pharmaceuticals, where he led global medical strategy for CNS products including APOKYN® for Parkinson's disease. Earlier in his career, he held progressive leadership roles at Takeda Pharmaceuticals and Shire (now Takeda), driving clinical development, medical affairs, and lifecycle management for neurology and gastroenterology portfolios. Dr. Dayno earned his M.D. from the University of Vermont College of Medicine, completed his neurology residency at the University of Pennsylvania, and a fellowship in movement disorders at the University of Pennsylvania. At Harmony, Dr. Dayno continues to champion patient-centric innovation, forging strategic partnerships and navigating regulatory landscapes to bring novel therapies to market. His achievements include positioning WAKIX as a market leader, securing expanded label indications, and building a high-performing team that has propelled the company's market capitalization and investor confidence, solidifying Harmony's role as a leader in rare disease therapeutics.